NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Study for the NAPLEX exam with a comprehensive quiz featuring multiple-choice questions and in-depth explanations. Build your pharmacological knowledge and increase your chances of passing the pharmacist licensure examination!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.

For the treatment of melanoma, which mutation must be present to use BRAF inhibitors?

BCR-ABL+
BRAF V600E or V600K mutation +
EGFR mutation positive
ALK mutation +

The correct answer is: BRAF V600E or V600K mutation +

B is the correct answer because BRAF V600E or V600K mutation is known to be present in most melanoma cases and is the primary driver for this cancer. This specific mutation activates the BRAF pathway which leads to the growth and survival of melanoma cells. It is important to use BRAF inhibitors in patients with this mutation because it specifically targets and blocks the effects of the mutated BRAF protein. A, C, and D are all incorrect because they refer to mutations that are not related to melanoma. BCR-ABL is a mutation associated with chronic myelogenous leukemia (CML), EGFR is associated with lung cancer, and ALK is associated with non-small cell lung cancer. Therefore, these mutations would not be present in melanoma and using BRAF inhibitors would not be effective in treating the cancer.